INNV EBITDA
$31.27MTTM · USD
Period ending:
INNV FY EBITDAUSD
$87.42M-$33.85M
2019-06-302026-06-30
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
INNV ebitda history
Earnings before interest, taxes, depreciation, and amortization. The available annual fiscal periods series contains 8 observations from Jun 30, 2019 to Jun 30, 2026.
| Period ending | EBITDA (USD) |
|---|---|
| 87,420,000 | |
| 3,364,000 | |
| 1,154,000 | |
| -33,852,000 | |
| 9,213,000 | |
| -5,888,000 | |
| 61,543,000 | |
| 45,918,000 |
Compare ebitda
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) ebitda
- Bridgebio Pharma Inc (BBIO) ebitda
- Brightspring Health Services Inc (BTSG) ebitda
- Madrigal Pharmaceuticals Inc (MDGL) ebitda
- Ensign Group Inc (ENSG) ebitda
- Glaukos Corp (GKOS) ebitda
- Vaxcyte Inc (PCVX) ebitda
- Krystal Biotech Inc (KRYS) ebitda
All INNV financial metrics · INNV stock overview · How to interpret financial metrics
